[Pharmacological management of inflammatory rheumatic conditions].
Inflammatory rheumatic disorders are related to different pathophysiological mechanisms           and, hence, their therapeutic management varies according to the underlying disease.           Crystal-induced arthritis is characterized by its almost specific responsiveness to           colchicine. Regarding ankylosing spondylitis, non steroidal anti-inflammatory drugs           (NSAIDs) and TNF blockers are the cornerstones of pharmacological intervention whereas           oral corticosteroids at conventional doses are of little value, if any. Conversely,           corticosteroids are the drug of choice to treat polymyalgia rheumatica. Furthermore,           low-dose corticosteroids were shown to be more effective than NSAIDs in patients with           rheumatoid arthritis (RA). However, the main goal being to achieve remission,           disease-modifying antirheumatic drugs, either synthetic, especially methotrexate, and/or           biologic, such as TNF inhibitors, have a major role in the management of RA. Finally,           enhanced understanding of molecular pathogenesis of inflammatory disorders may help to           find out how to best target available drugs to right individuals in the future.
Universite Victor Segalen, Bordeaux, France. bernard.bannwarth@u-bordeaux2.fr
Bernard
B
Bannwarth
D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001168:Arthritis / Q000188:drug therapy; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D003078:Colchicine / Q000627:therapeutic use; D006073:Gout / Q000188:drug therapy; D006074:Gout Suppressants / Q000627:therapeutic use; D006801:Humans; D007249:Inflammation / Q000188:drug therapy / Q000473:pathology; D011111:Polymyalgia Rheumatica / Q000188:drug therapy; D012216:Rheumatic Diseases / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D025241:Spondylarthritis / Q000188:drug therapy
D018501:Antirheumatic Agents; D006074:Gout Suppressants; D003078:Colchicine